The mini bone marrow model predicts the response to the treatment of the blood disorder


Platelets are created and released into the bloodstream by megakaryocytes, giant cells that live in the bone marrow. This image shows megakaryocytes (in red) forming platelets within a bone marrow mimicry made of silk biomaterial. Credits: Christian Di Buduo, Alessandra Balduini (CC BY 4.0)

A new 3D miniature model of human bone marrow has been described today in open access eLife magazine.

The model can help clinicians predict which patients will benefit from one per platelet , such as inherited thrombocytopenias: a group of familial disorders that inhibit platelet production. It could also allow for a later study of these disorders and provide scientists with a new tool for testing experimental treatments.

Platelets are cells needed for blood to clot and stop bleeding. Having too few platelets can cause internal or severe bleeding after surgery or injury, which is usually treated with therapies that cause clotting. Recent studies have shown that a drug called Eltrombopag increases platelet production, but not all patients appear to benefit from it. “Patients with the same apparent form of platelet disorder may respond differently to treatment with Eltrombopag,” says lead author Christian Di Buduo, adjunct research professor in the Department of Molecular Medicine at the University of Pavia, Italy.

To help determine which patients might benefit from the drug, Di Buduo and colleagues developed a mini 3D model of human bone marrow that combines a silk protein scaffold and cell culture derived from the patient to recreate the human bone marrow environment where platelets occur. “This device is a significant improvement over previous models, requiring only a very small sample of blood to recreate platelet production,” explains Di Buduo.

Then the team tested what happened when they added Eltrombopag to one of a patient with a platelet disorder who had previously been treated with the drug. Their results showed that the number of platelets produced in the model corresponded to the way each patient had responded to treatment with Eltrombopag. The increase in the number of platelets collected from the model was comparable to the increase in the number of platelets in the blood of patients after treatment.

The authors say that could eventually lead to a personalized treatment for disorders helping clinicians match to the best treatment.

“This easy-to-reproduce system can also help scientists better understand what happens to these disorders and how treatments work, as well as provide them with a new tool to test new drugs that can lead to improved therapies in the future,” he concludes. lead author Alessandra Balduini, principal investigator and professor at the University of Pavia.

Scientists visualize competition between healthy and dysfunctional platelets

More information:
Christian A Di Buduo et al, a 3D miniaturized bone marrow tissue model to evaluate the response to thrombopoietin receptor agonists in patients, eLife (2021). DOI: 10.7554 / eLife.58775

Newspaper information:

Citation: Mini Bone Marrow Model Predicts Response to Blood Disorder Treatment (2021, June 1) Retrieved June 2, 2021 from -marrow-response-blood.html

This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link